HR 63

RU-486 Suspension and Review Act of 2007

Congress: 110 (2007–2009, Ended)
Chamber: House
Policy Area: Health
Introduced: Jan 4, 2007
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Feb 2, 2007)
Official Text: https://www.congress.gov/bill/110th-congress/house-bill/63

Sponsor

Name: Rep. Bartlett, Roscoe G. [R-MD-6]
Party: Republican • **State:** MD • **Chamber:** House

Cosponsors (48 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Alexander, Rodney [R-LA-5]	R · LA		Jan 17, 2007
Rep. Blackburn, Marsha [R-TN-7]	R · TN		Jan 17, 2007
Rep. Davis, Geoff [R-KY-4]	R · KY		Jan 17, 2007
Rep. Davis, Jo Ann [R-VA-1]	R · VA		Jan 17, 2007
Rep. Davis, Lincoln [D-TN-4]	D · TN		Jan 17, 2007
Rep. Fortenberry, Jeff [R-NE-1]	R · NE		Jan 17, 2007
Rep. Franks, Trent [R-AZ-2]	R · AZ		Jan 17, 2007
Rep. Gingrey, Phil [R-GA-11]	R · GA		Jan 17, 2007
Rep. Goode, Virgil H., Jr. [R-VA-5]	R · VA		Jan 17, 2007
Rep. Herger, Wally [R-CA-2]	R · CA		Jan 17, 2007
Rep. Hoekstra, Peter [R-MI-2]	R · MI		Jan 17, 2007
Rep. King, Steve [R-IA-5]	R · IA		Jan 17, 2007
Rep. Lewis, Ron [R-KY-2]	R · KY		Jan 17, 2007
Rep. Manzullo, Donald A. [R-IL-16]	R · IL		Jan 17, 2007
Rep. Musgrave, Marilyn N. [R-CO-4]	R · CO		Jan 17, 2007
Rep. Norwood, Charles W. [R-GA-10]	R · GA		Jan 17, 2007
Rep. Sali, Bill [R-ID-1]	R · ID		Jan 17, 2007
Rep. Smith, Christopher H. [R-NJ-4]	R · NJ		Jan 17, 2007
Rep. Wicker, Roger F. [R-MS-1]	R · MS		Jan 17, 2007
Rep. Wilson, Joe [R-SC-2]	R · SC		Jan 17, 2007
Rep. Boozman, John [R-AR-3]	R · AR		Feb 5, 2007
Rep. Ehlers, Vernon J. [R-MI-3]	R · MI		Feb 5, 2007
Rep. Hall, Ralph M. [R-TX-4]	R · TX		Feb 5, 2007
Rep. Hayes, Robin [R-NC-8]	R · NC		Feb 5, 2007
Rep. Hensarling, Jeb [R-TX-5]	R · TX		Feb 5, 2007
Rep. Hunter, Duncan [R-CA-52]	R · CA		Feb 5, 2007
Rep. Jones, Walter B., Jr. [R-NC-3]	R · NC		Feb 5, 2007
Rep. Murphy, Tim [R-PA-18]	R · PA		Feb 5, 2007
Rep. Pitts, Joseph R. [R-PA-16]	R · PA		Feb 5, 2007
Rep. Renzi, Rick [R-AZ-1]	R · AZ		Feb 5, 2007
Rep. Shimkus, John [R-IL-19]	R · IL		Feb 5, 2007
Rep. Sullivan, John [R-OK-1]	R · OK		Feb 5, 2007
Rep. Terry, Lee [R-NE-2]	R · NE		Feb 5, 2007
Rep. Tiahrt, Todd [R-KS-4]	R · KS		Feb 5, 2007
Rep. Tiberi, Patrick J. [R-OH-12]	R · OH		Feb 5, 2007
Rep. McCotter, Thaddeus G. [R-MI-11]	R · MI		Mar 13, 2007
Rep. Westmoreland, Lynn A. [R-GA-3]	R · GA		Mar 13, 2007
Rep. Everett, Terry [R-AL-2]	R · AL		Mar 21, 2007
Rep. LaHood, Ray [R-IL-18]	R · IL		Mar 21, 2007
Rep. Schmidt, Jean [R-OH-2]	R · OH		Mar 21, 2007
Rep. Bachus, Spencer [R-AL-6]	R · AL		Mar 28, 2007

Cosponsor	Party / State	Role	Date Joined
Rep. Chabot, Steve [R-OH-1]	R · OH		Apr 17, 2007
Rep. Whitfield, Ed [R-KY-1]	R · KY		Apr 17, 2007
Rep. Inglis, Bob [R-SC-4]	R · SC		May 24, 2007
Rep. Rogers, Harold [R-KY-5]	R · KY		Jun 13, 2007
Rep. Souder, Mark E. [R-IN-3]	R · IN		Sep 6, 2007
Rep. Lamborn, Doug [R-CO-5]	R · CO		Mar 10, 2008
Rep. Foxx, Virginia [R-NC-5]	R · NC		May 20, 2008

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 2, 2007

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jan 4, 2007)

RU-486 Suspension and Review Act of 2007 - Deems the approved application for the drug mifepristone (marketed as Mifeprex, commonly known as RU-486, and used for the chemically induced termination of intrauterine pregnancy) to have been withdrawn.

Deems the drug misoprostol to be misbranded under the Federal Food, Drug, and Cosmetic Act (FFDCA) if it bears labeling providing that the drug may be used for the medical termination of intrauterine pregnancy.

Directs the Comptroller General to review and report on the process by which the Food and Drug Administration (FDA) approved mifepristone. Provides for the reinstatement of the approved application for such drug if the report determines the approval to have been in accordance with FFDCA.

Actions Timeline

- **Feb 2, 2007:** Referred to the Subcommittee on Health.
- **Jan 4, 2007:** Introduced in House
- **Jan 4, 2007:** Referred to the House Committee on Energy and Commerce.